Companies: 10,795·Total market cap: $144.5T
Marvel Biosciences Corp.

Marvel Biosciences Corp.

MRVL.VTSXVHealthcare● Active
$0.20
+$0.00(+2.56%)
Market Cap$12290517
P/E Ratio
52W High$0.4
52W Low$0.09

Marvel Biosciences Corp. (MRVL.V) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

mrvl.v · pe ratio · data through Jul 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Marvel Biosciences Corp. (MRVL.V) measures how much investors pay for each dollar of the company's trailing earnings. MRVL.V's current PE ratio of N/A is calculated by dividing its stock price of $0.20 by its TTM earnings per share of -$0.04.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-07-31

Forward P/E
N/A
EPS (TTM)
-$0.04
TTM · diluted EPS
PEG Ratio
1.17
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Marvel Biosciences Corp. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Marvel Biosciences Corp.
Marvel Biosciences Corp.You
MRVL.V
$12MN/A-$0.04
BetterLife Pharma Inc.
BetterLife Pharma Inc.
BETR.CN
$11MN/A-$0.01
BioVaxys Technology Corp.
BioVaxys Technology Corp.
BIOV.CN
$2MN/A-$0.20
Britannia Life Sciences Inc.
Britannia Life Sciences Inc.
BLAB.CN
$14M1.65x$0.05
Comprehensive Healthcare Systems, Inc.
Comprehensive Healthcare Systems, Inc.
CHS.V
$10MN/A-$0.15
Delivra Health Brands Inc.
Delivra Health Brands Inc.
DHB.V
$4MN/A-$0.04
Glow Lifetech Corp.
Glow Lifetech Corp.
GLOW.CN
$10MN/A-$0.00

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-07-31Latest
FY2025
$-0.05
2024-07-31
FY2024
$-0.00
2023-07-31
FY2023
$-0.06
2022-07-31
FY2022
$-0.08
2021-07-31
FY2021
$-0.09
2020-07-31
FY2020
$-0.13
2019-07-31
FY2019
$-0.03

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Marvel Biosciences Corp. (MRVL.V) measures how much investors pay for each dollar of the company's trailing earnings. MRVL.V's current PE ratio of N/A is calculated by dividing its stock price of $0.20 by its TTM earnings per share of -$0.04.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.20 ÷ -$0.04 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

MRVL.V pe ratio · 6 questions

MRVL.V's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.20 and TTM EPS of -$0.04. Data sourced from Financial Modeling Prep via MRVL.V's SEC 10-K and 10-Q filings.

MRVL.V PE ratioWhat is MRVL.V PE ratioCurrent PE ratio of MRVL.VMRVL.V PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Marvel Biosciences Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08